Put companies on watchlist
Bank of America Securities Europe SA
ISIN: DE000A3ENQ51
WKN: A3ENQ5
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Bank of America Securities Europe SA · ISIN: DE000A3ENQ51 · EQS - Company News (22 News)
Country: France · Primary market: Germany · EQS NID: 1742835
06 October 2023 08:00AM

Exercise of the Greenshoe Option and Post-stabilisation Period Announcement


EQS-News: Bank of America Securities Europe SA / Key word(s): IPO
Bank of America Securities Europe SA: Exercise of the Greenshoe Option and Post-stabilisation Period Announcement

06.10.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

6 October 2023

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

SCHOTT Pharma AG & Co. KGaA

 

Exercise of the Greenshoe Option and Post-stabilisation Period Announcement

 

Further to the pre-stabilisation period announcement dated 27 September 2023, BofA Securities Europe SA (contact: Victor Dumas Vorzet; telephone: +33187701048) hereby gives notice that the Stabilisation Manager named below has fully exercised the over-allotment/greenshoe option (of up to 4,518,438 shares) on 6 October 2023 in respect of 4,518,438 shares at the offer price of EUR 27.00 per share and that the stabilisation period has been concluded early on 6 October 2023. During the stabilisation period, the Stabilisation Manager did not undertake stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/2016/2014), and also as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) in relation to the offer of the following securities, as set out below.

 

Issuer: SCHOTT Pharma AG & Co. KGaA (“SCHOTT Pharma“)
Description: -Offering of existing ordinary bearer shares with no par value of SCHOTT Pharma
-ISIN: DE000A3ENQ51
-WKN: A3ENQ5
-Ticker: 1SXP
Offer size: 30,122,924 shares (excluding the over-allotment option)
Stabilisation Manager: BofA Securities Europe SA, 51 rue la Boétie, 75008 Paris
Offer price: EUR 27.00
Stabilisation started: 28 September 2023

 

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States.

 



06.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1742835  06.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1742835&application_name=news&site_id=boersengefluester
Visual performance / price development - Bank of America Securities Europe SA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.